Figure 3From: Predictive value of the SLC22A18 protein expression in glioblastoma patients receiving temozolomide therapySLC22A18 promoter methylation status and protein expression when compared with overall survival time of cases. Results of Kaplan-Meier analyses of overall survival time according to SLC22A18 protein expression (A and B) or promoter methylation (C and D) of GBM patients with TMZ therapy (A and C) and without TMZ therapy (B and D) are shown.Back to article page